Using isolated, in situ, single-pass perfused rat livers, incubations of freshly isolated hepatocytes, and sinusoidal membrane-enriched vesicles, we and others have shown the saturability of transport (efflux) of hepatic glutathione (GSH). These observations have implicated a carrier mechanism. Our present studies were designed to provide further evidence in support of a carrier mechanism for hepatic GSH efflux by demonstrating competition by liver-specific ligands which are taken up by hepatocytes. Perfusing livers with different substances, we found that: (a) sulfobromophthalein-GSH (BSP-GSH) had a dose-dependent and fully reversible inhibitory effect on GSH efflux, while GSH alone did not have any effect; (b) taurocholate had no inhibitory effect; (c) all of the organic anions studied, i.e., BSP, rose bengal, indocyanine green, and unconjugated bilirubin (UCB), manifested potent, dose-dependent inhibitory effects, with absence of toxic effects and complete reversibility of inhibition in the case of UCB. The inhibitory effects of UCB could be overcome partially by raising (CoC12-induced) hepatic GSH concentration.
Introduction
Glutathione exists in high concentrations (5-7 mM) in the liver, chiefly in the reduced form (GSH), and plays a major role in many detoxification and regulatory processes (1) . The efflux of GSH from the liver is estimated to account for nearly all of hepatic GSH turnover (2) . Using the isolated, perfused rat liver and freshly isolated hepatocyte systems, we have previously shown that sinusoidal efflux of GSH is saturable and thus, presumably, carrier mediated (3, 4) . The saturability and transstimulation of GSH transport have been shown in sinusoidal membrane-enriched vesicles (5, 6) .
In our initial work (3), we had conducted some preliminary experiments with sulfobromophthalein (BSP)'-GSH and had found that it could inhibit GSH efflux from the perfused rat liver. This outcome further supported the view that sinusoidal effilux of GSH is carrier mediated. Since BSP-GSH is an organic anion, we have examined the effect on GSH transport of several such molecules known to be taken up by hepatocytes.
To accomplish this aim, we used the isolated, in situ, perfused rat liver system to screen organic anions (dyes), bilirubin, and taurocholate to find out whether they have any inhibitory effect on the GSH efflux. Since, among the compounds that exerted an inhibitory effect, bilirubin was the physiologically relevant and important organic anion, we studied the kinetics of its inhibitory effect on GSH efflux in more detail, using freshly isolated hepatocyte incubations. We extended our investigations to delineate whether the inhibitory effect is exerted from outside or inside the hepatocytes, as well as to identify the molecular form(s) of bilirubin (i.e., unconjugated vs. glucuronide forms) responsible for inhibition.
Methods
Chemicals and reagents. GSH, unconjugated bilirubin (UCB), collagenase (type IV), bovine serum albumin, organic anion dyes (BSP, rose bengal, and indocyanine green) and Hepes were purchased from Sigma Chemical Co. (St. Louis, MO). HPLC-grade methanol was purchased from Fisher Scientific Co. (Springfield, NJ). All other materials used were of analytic reagent grade and were obtained from commercial sources.
Animals. Male Sprague-Dawley rats (Hilltop Laboratory Animals, Inc., Scottdale, PA), 200-300 g, were maintained on Purina rodent chow (Ralston Purina Co., St. Louis, MO) and water ad libitum. To induce an increased hepatic GSH concentration, some rats received CoCl2 injections as described previously (3) . The cumulative doses given in our present study were 80-100 mg of CoCl2/kg.
Male hetero-and homozygote Gunn rats, 300-450 g, used in our studies were a generous gift of Dr. Anthony McDonagh of University ofCalifornia, San Francisco, Liver Center. The distinct yellow color of the sera and the HPLC analysis ofbile samples (see below), to establish the absence ofbilirubin monoglucuronide (BMG) and bilirubin diglucuronide (BDG), were utilized as criteria for the acceptability of any homozygote Gunn rat used in our studies.
Liver perfusions and hepatocyte incubations. The design, method, and the apparatus described earlier (3) were used for our isolated, in 1 . Abbreviations used in this paper: BMG and BDG, bilirubin monoand diglucuronide; BSP, sulfobromophthalein; ECF, extracellular fluid; UCB, unconjugated bilirubin. situ perfusions. The perfusion rates using oxygenated Krebs-Ringer bicarbonate buffer were 3.85±0.04 ml/min * g liver, perfusion pressures were 5.5±0.3 cm H20, and the 02 uptakes were 2.13±0. 03 ,pmol/min * g liver (mean±SEM, n = 60-63). These values compare very closely to those reported in our earlier studies (3) . We had also established that glutathione efflux from the perfused liver is virtually all in the form of GSH, i.e., reduced glutathione (3) . Perfusions with Cl--free media were done with replacement of NaCl and KCl in the Krebs-buffer with equimolar sucrose. In all cases, glutathione S-transferase was measured in the perfusates, as before (3), and found to indicate no lysis.
Hepatocytes were isolated by the recirculating collagenase perfusion method of Moldeus et al. (7) , and handled as described earlier (4). Cells were 2 93% viable at the onset of each incubation, as ascertained by 0.2% trypan blue exclusion and quantitation of extracellular fluid (ECF) glutathione S-transferase (4), a cytosolic enzyme marker. Incubations were routinely carried out with 106 cells/ml (total initial volume = 10 ml). Our previous studies have established that practically all of glutathione effluxing from isolated hepatocytes is in the form of GSH. Additions of all compounds to be studied were made just before the suspension of hepatocytes to the Krebs-Henseleit buffer, supplemented with 12.5 mM Hepes at pH 7.4 and 370C in 25-ml Erlenmeyer flasks. Thereafter, at the onset of each incubation, washed hepatocytes were suspended and rapidly dispersed in the incubation media. The flasks containing cell suspensions were quickly returned to the heating shaker bath. About 1-2 min was allowed for temperature equilibration and settlement of any transient disturbances, after which the first sample was taken and expressed as t = 0 sample. Incubations were done under room air with gentle shaking and periodic samples of cell suspension (1 ml) were removed for immediate separation of cells and ECF (5-s centrifugation on Beckman Instruments Microfuge) for subsequent assays and analyses. Cell lysis was measured during the course ofincubation by the measurement of released glutathione S-transferase and the results were used to correct the ECF data for contributions made by cytosolic contents due to lysis. The cumulative lysis throughout our incubations generally remained well below 10%. Certain control incubations were carried out in the absence of hepatocytes (cellfree incubations), or with hepatocytes but at < 4°C, as described in Results. Cl--free incubations were done using an equimolar sucroseHepes buffer. In incubations with UCB, BMG, and BDG, bovine serum albumin was also added to the incubation media, just prior to the addition of these compounds. The initial molar ratio of bilirubin moieties to albumin was set at -1. Detectable effects on the ECF GSH were observable only at albumin concentrations . 0.5% (. 75 ,uM). However, this effect is due to the promotion of mixed disulfide formation in response to elevated albumin levels (unpublished observations). For our present studies, all incubations were done with < 0.5% albumin.
After complete removal of the supernatants of centrifuged incubation samples, the cell pellets (106 cells) were ordinarily resuspended in buffer (0.5 ml) and cellular GSH was extracted with addition of 10% trichloroacetic acid (1:1, vol/vol), as described before (4) . Whenever cellular bilirubin measurements were required, the pellets were extracted with 0.5 ml of HPLC-grade methanol (Fisher Scientific Co.). Our trials established that a single extraction step with 0.5 ml ofmethanol could recover 80% of the total cellular unconjugated and glucuronide forms of bilirubin that could be recovered with a total of four successive extractions with methanol (levels of bilirubin in additional washes fell below the detection levels of our methods). This one-step extraction efficiency, i.e. 80%, was the same for the recovery ofcellular GSH content by 0.5-ml methanol extraction, as compared to buffer + trichloroacetic acid extraction. Thus, in extractions of cell pellets with methanol, we used a correction factor (multiplication by 1/0.8 = 1.25) to estimate the true cellular values, based on an 80% efficiency of extraction.
In our studies, perfused livers from ad lib-fed rats of different groups had average GSH concentrations in the typical range of [5] [6] umol/g. Isolated hepatocytes averaged at -40 nmol/106 cells or 4 Amol/g liver of GSH (108 cells = 1 g), except for the CoCl2-treated group which reached an average value of -7 7mol/g. Mean±SEM for each group is presented in the tables and the legends to the figures.
To measure the total glutathione S-transferase content of the cells used in any incubation, additional samples of 106 pelleted cells were resuspended in 0.5 ml of buffer and digested with 10% triton X-100 (1:1, vol/vol). All resuspended pellets treated with trichloroacetic acid, methanol, or Triton X-100 were again centrifuged in a Microfuge and the supernatants were used for subsequent analyses. The cumulative lysis during 1-h incubations usually was well below 10% of total cell population. The values of GSH in the medium were corrected for the contribution by lysis, as before (4) .
Assays. GSH in perfusates and incubation media (ECF) were measured by the recycling assay of Tietze (8) . Whenever addition of other compounds (i.e., organic anion dyes, bile acids and bilirubin in conjugated or unconjugated form) was made, we ascertained that their presence had no effect on determination of GSH values under our assay conditions. Hepatic GSH was measured by the Owens and Belcher (9) method, as described previously (3) . Perfused liver homogenates, or resuspended cell pellets were precipitated with 10% trichloroacetic acid (1:1 vol/vol) and the supernatants were assayed for GSH. Glutathione S-transferase was measured by the formation of the conjugate of 1-chloro-2,4-dinitrobenzene-GSH conjugate, as before (3, 4) .
Organic anion dyes were measured by direct spectrophotometric assays after scanning for determination of their peak absorbance. Thus, BSP and BSP-GSH conjugate (the latter prepared by the method described by Whelan et al. [10] ) were assayed at 580 nm (under alkaline conditions), rose bengal at 550 nm, and indocyanine green at 800 nm.
Bilirubin solutions and HPLC analysis. All preparations, purifications, handling, and use in perfusions or incubations of UCB and BMG were done under very dim lighting. Intermediate storage of compounds was under total darkness at -16'C. In addition, freshly purified BMG and BDG were stored under 99.99% argon at -16°C for no longer than overnight, before use.
Fresh stock solution of UCB (5 mM in 100 mM Na2CO3) was prepared, according to the method described by Paumgartner and Reichen (1 1), just before use in perfusions or incubations. The stock solution was then diluted to the desired concentration to obtain a molar ratio of UCB:bovine serum albumin of 1:1. Control incubations with the highest concentration of Na2CO3 alone (without bilirubin), used in our experiments, showed no effect on the GSH efflux or any other parameter.
To obtain BMG, we used the preparative gradient HPLC method described by Spivak and Carey (12) . First, to obtain BMG-and BDGrich bile, we infused 50 Al/min of 1 mM UCB (diluted in 0.9% NaCl from the 5 mM stock solution described above) i. (12) using a flow rate of 3.5 ml/min. The buffers used for HPLC were gassed with the high-purity argon. BDG fraction eluted with a retention time of8-9 min and BMG fraction with a retention time of 13-14 min. These fractions were collected in three equal lots (-5 ml each) and concentrated down (to < 0.5 ml each) under a stream of high-purity argon at room temperature. The concentrated samples were subsequently desalted by Sep-Pak C18 cartridges (Waters Associates, Milford, MA), with all steps carried out using ice-cold, argon-gassed double-distilled water and HPLCgrade methanol as follows. Each cartridge was wetted by 5 ml ofwater. The concentrated sample was loaded onto the cartridge and washed with 3 ml of water. Thereafter, BMG or BDG was eluted by 2-3 ml of methanol. These desalted samples were evaporated down to near dryness under a high-purity argon stream at room temperature and stored overnight at -16'C. On the following morning, the specimens were taken to complete dryness to eliminate any traces of methanol. Thereafter, BMG or BDG were resuspended at the desired concentration in the incubation media containing bovine serum albumin just before the addition of the hepatocytes, as described earlier.
To analyze the perfusate, or incubation media (ECF) samples, for UCB, BMG, and BDG, a fivefold (vol/vol) dilution ofeach sample was made with HPLC-grade methanol to precipitate the proteins, in preparation for loading the sample onto the analytical column. Cell-associated bilirubin was extracted with 0.5 ml HPLC-grade methanol, as stated before, and after centrifugation (5 s on a Microfuge), the supernatant was injected onto the column. The analytical column was an Altex Ultrasil-ODS, reverse-phase column (10 , run to quantitate all forms of bilirubin, based on the reported identity of the extinction coefficients of the different moieties ( 13) .
Results
Inhibition ofsinusoidal GSH effluxfrom the perfused liver by BSP-GSH We had previously reported the ability of -10 MM of BSP-GSH to inhibit (by 30%) the sinusoidal GSH efflux from the isolated, perfused rat liver (3). In our present studies, we first extended our observations over a range of BSP-GSH concentrations to establish whether there is a dose dependence between the inhibitor concentration and GSH efflux. In these perfusions, after an initial control period, a 30-min step infusion of BSP-GSH was given (data not shown; refer to Fig. 1 showing the design and data from similar studies using UCB). About 15 min after the onset ofthe infusion, the declining rate of GSH efflux reached a near plateau. Later, when the BSP-GSH infusion was stopped, the efflux recovered in about 15 min to control (pre-BSP-GSH) levels. Thus, the inhibitory effect of BSP-GSH was completely reversible. There were also no adverse effects manifested throughout these perfusions as evidenced by the 02 uptake values, which remained at typical control levels (3); absence of breakdown of the liver, as monitored by the release ofGSH S-transferase in the perfusates; and steadiness of pressure throughout each perfusion.
We used the average value of the data points defining the plateau value of inhibited efflux (15-30 min after onset of infusion) to compute and express the inhibition of GSH efflux as the percentage ofthe mean control (uninhibited) efflux. The results of a number of perfusions conducted with different doses of BSP-GSH revealed a dose dependence between the inhibition of GSH efflux and perfusate BSP-GSH concentration (Table I ). The corresponding rates of uptake of BSP-GSH by livers were measured by the difference in the inflow-outflow concentrations of BSP-GSH in the perfusates during the plateau phase of inhibition (Table I ). The concentration of BSP-GSH in the effluent perfusate fell to undetectable levels in less than 2 min after the cessation of its infusion into the perfusion line.
Effect ofbile acids and organic anion dyes on sinusoidal GSH effluxfrom the perfused liver Taurocholate, at the range ofconcentrations tested, i.e., 5-100 MM (n = 3), did not exert any inhibitory effect on the efflux of Values given as mean±SEM.
* See text for details of design. The livers were from normal, adlib-fed rats with 5.3 ± 0.4 umol GSH per g liver. I % Inhibition (from control efflux) was calculated using the mean of data points in the 15-30 min period after the onset of BSP-GSH infusion.
n, number of perfusions. The rate of control (uninhibited) effilux for the total number of livers used in this study was 15.2±0.9 nmol GSH/min * g liver.
GSH. On the other hand, all ofthe organic anion dyes tested in two to three separate perfusions exerted potent inhibitory effects on the GSH efflux with 10-15 uM BSP exerting 30-50% inhibition, 4 uM rose bengal inhibiting by 50%, and 1.5-2.0 ;tM indocyanine green inhibiting by 40-45%. The inhibitory effect of these three dyes was accompanied by toxic manifestations, such as declining 02 uptake, progressively increasing pressure (resistance to flow) during the infusion ofthe dye, and incomplete recovery ofthe GSH effilux to control levels following the cessation of the infusion of these compounds (data not shown).
Inhibition ofsinusoidal GSH effluxfrom the perfused liver by bilirubin and the effect ofhepatic GSH concentration Since bilirubin is a physiologically relevant and important organic anion, we were interested in determining if, in the range of normal plasma concentrations of UCB (< 20 IAM), it would exert any inhibitory effect on the GSH efflux from the perfused liver. UCB caused an inhibition of the GSH efflux which was not accompanied by the toxic manifestations observed with the dyes. In fact, it was possible to conduct perfusions with two successive and increasing doses of UCB on the same liver, a sample of which is presented in Fig. 1 . As can be seen, after each step infusion of UCB, the GSH efflux arrived at a near plateau in 15 min, after the onset of each respective dose of infusion.
A group of perfusions was done on livers with normal hepatic GSH levels, as well as a group with elevated hepatic GSH levels (CoCl2-induced) to determine if raising intracellular GSH would overcome the inhibitory effect of UCB (presumably by competition for the carrier). As seen in Table II , there was a dose-dependent inhibition of GSH efflux. In addition, significantly less inhibition of GSH efflux was observed in livers with elevated GSH compared to the livers with normal GSH. The rate of uptake of UCB increased with increasing concentrations in the perfusate, but was indistinguishable between normal and CoCl2-treated groups. Normal and CoCl2-treated livers had indistinguishable GSH effluxes due to both values being near saturation levels (pooled value of efflux shown in the footnote to Table II) . Thus, apparently, elevated hepatic GSH did not overcome inhibition by a greater absolute rate of efflux of GSH, or a decreased rate of uptake of UCB.
Kinetics ofthe inhibition by bilirubin ofGSH effluxfrom freshly isolated hepatocytes and the effect ofcellular
GSH concentration
To extend our findings with UCB in the perfused liver, and to study the kinetics and characteristics of inhibition in more detail, we turned to the isolated cell system. The results from a sample experiment are shown in Fig. 2 , which also presents the design of these incubation experiments. As before (4, 14) , the appearance of GSH in the incubation medium (referred to as ECF) was nearly linear and accompanied by a concurrent drop in the cellular GSH, such that the total (cells + ECF) GSH remained near-constant, or decreased slightly, in 30-60-min incubations. Thus, as before (4, 14) , these hepatocytes were not synthesizing any net amount of GSH de novo during our incubations, and the decline of cellular GSH was almost quantitatively accounted for by the loss due to efflux. The rate of efflux in each incubation was estimated with the slope of the linear regression fit to the ECF GSH data, as shown in Fig. 2 . As can be seen, doses as low as 1 and 5 MM ECF UCB were capable of inhibiting the GSH efflux in comparison to control. We have verified that the fall in the rate of GSH efflux due to UCB was not accompanied by a fall in the cellular ATP levels (Fernandez-Checa et al., manuscript submitted for publication) or generally reduced transport functions, as checked with
["4C]glycine uptake (data not shown). suspension of hepatocytes in the medium containing 20 M UCB (-2 min to the onset of t = 0 for our kinetic measurements), there was a considerable initial drop (-25%) in the ECF UCB. This drop was present, even at 4VC incubation and in ECF samples taken as quickly as it was feasible, i.e., a few seconds, after the suspension of cells. However, whereas in 370C incubations there was a further continuous decline in the ECF UCB to concentrations below 10 AM at 60 min, there was no further fall in the 4VC incubations. Cell-free control incubations conducted in parallel at 370C showed no spontaneous decline of ECF UCB; thus, post zero-time disappearance of ECF UCB was caused by the presence ofcells due to continued binding/uptake of UCB. Cell UCB values (Fig. 3) showed the presence of a large early component, correlated with the initial rapid fall observed in the ECF UCB. This high, near-instantaneous, cell-associated value is probably due to the binding of bilirubin to the cell surface and exterior of the plasma mem-brane of hepatocytes. Thus, the cell-associated UCI values at any time point represent a combination of a large membranebound component and the intracellular UCB. Therefore, at any given time point, it is not possible to accurately determine the fraction of cell-associated UCB that is truly intracellular. Whereas cell UCB. accumulated to a constant level in 4VC incubations, in 370C incubations it reached an early peak and subsequently declined. The additional decline was presumably due to conjugation and metabolism of UCB to BMG (and BDG) as shown in Fig. 3 . Cell BMG also rose to a peak and declined in 370C incubations, while it remained undetectable in 4VC incubations, consistent with the apparent lack of metabolism manifested by the ECF and cell UCB data. Table IV shows the summary of the results from these experiments. As can be seen, the GSH efflux from cells incubated with 5% albumin recovered to levels indistinguishable from control. However, cells resuspended in albumin-free medium, retained an inhibited level of GSH efflux (i.e., 41% of control) in the total absence of any extracellular UCB. This degree of inhibition was close to the original level of inhibition measured in the presence of 20 ,uM extracellular UCB (i.e., 44% of control). Molecular form. To delineate whether it is the unconjugated or the conjugated form ofbilirubin that is responsible for inhibition of GSH efflux, we did the following set of studies.
To clarify whether UCB alone can exert an inhibitory effect, we used hepatocytes obtained from Gunn rats. Heteroand homozygote Gunn rat hepatocytes were incubated in the same way as those from Sprague-Dawley rats, described above. Table V presents the results of these experiments. In both groups of cells (homozygote and heterozygote) addition of UCB caused the inhibition (dose-dependent) of GSH efflux from hepatocytes. However, while heterozygote cells were producing BMG and BDG during the incubation, there were no detectable traces of BMG (and BDG) in the cells from homozygote Gunn rats (not shown). Thus, it was clear that UCB alone, without being converted to BMG and BDG, could inhibit the GSH effilux.
After delineation ofthis point, the possibility still remained that BMG and BDG were also capable of inhibiting the GSH efflux. Therefore, we performed a group of experiments using BMG and BDG purified by the preparative HPLC method of Spivak and Carey (12), as described in Methods. The effect of BMG was studied more extensively than the BDG in an attempt to define its kinetics of inhibition. The disappearance of ECF BMG in 1-h incubations was similar to that observed with UCB in cells from Sprague-Dawley and Gunn rats (not shown), with negligible spontaneous disappearance of ECF BMG in cell-free incubations. Also the main difference from UCB data was that the initial, rapid fall of ECF BMG was only a small fraction of that of UCB. The fractional inhibition of GSH efflux by BMG was indistinguishable among the different cell types, i.e., Sprague-Dawley, heterozygote and homozygote Gunn rats. Hence, the data showing the inhibitory kinetics for all cell types have been pooled and presented in Fig.  5 . As can be seen, there was a dose-dependent inhibition of GSH efflux by BMG, similar to that observed with UCB.
The effect of BDG was verified only for initial ECF BDG of 2.21±0.2 uM in 5 cell preparations and found to decrease the hepatocellular GSH efflux to 57.2±6.3% of control (uninhibited) efflux.
Discussion
Using isolated, in situ, single-pass rat liver perfusions and freshly isolated hepatocyte incubations, we have reported essentially identical kinetics of sinusoidal GSH effilux as a func- (3, 4) . Thus, the saturability of the transport rate implicated the possible involvement of a carrier mechanism. However, saturability is a necessary, but not a sufficient criterion for carrier-mediated processes. Two additional qualifying criteria were verified and met subsequently. One, i.e. transstimulation, was demonstrated in the sinusoidal membraneenriched vesicle model (6) . The other, the ability of other but similar molecules to compete with and inhibit the transport of GSH, was confirmed with BSP-GSH in our preliminary work (3). In our present work, we have attempted to explore the generality of the inhibitory phenomenon by extending our observations to other organic anions. We have found that a bile acid transported by a carrier mechanism, i.e., taurocholate (studied up to 100 MM), had no effect on the sinusoidal GSH efflux from the perfused liver. In contrast, all of the organic anions screened, i.e., BSP, rose bengal, indocyanine green, and UCB, at rather low concentrations, i.e., [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] ,M, were able to inhibit the sinusoidal GSH efflux from the perfused rat liver. However, the effect of all ofthe tested organic anions, with the exception of UCB, was accompanied by toxic manifestations, i.e., declining hepatic 02 uptake, increasing perfusion pressure (resistance to flow), and incomplete recovery of GSH efflux to pre-organic anion infusion (control or uninhibited) values. Since bilirubin is a physiologically relevant and important organic anion, we extended our study of its detailed kinetics of inhibition of GSH effilux using the freshly isolated hepatocyte system. Incubations of the hepatocytes with physiological circulating levels of UCB, i.e., . 20 1AM, resulted in potent, dosedependent inhibitory effects (up to -70% inhibition) that could be partially overcome by raising the cellular GSH concentrations. (Note: We do not know whether the mechanism by which the cellular GSH is raised will have effects on the outcome of our studies. CoCl2 treatment does not affect the magnitude of sinusoidal GSH efflux, which remains at maximal saturation levels. Thus, it presumably increases the hepatic GSH pool size by increasing the synthetic rate.) We also ruled out the possibility that falling cellular ATP levels were the cause of falling GSH efflux in response to UCB, and verified that UCB had no effect on the uptake of ['4Clglycine during our incubations (up to 1 h). Thus, these observations were consistent with the view of UCB competitively inhibiting the GSH carrier. It should be noted that in isolated cells an uncertain but significant portion of the GSH efflux could represent the canalicular equivalent. Substantial canalicular GSH efflux occurs in the intact liver (16) , and some organic anions can inhibit this component (17) . BSP-GSH does not affect canalicular GSH transport (17, 18) . However, the effects of UCB and glucuronides have not been examined. Therefore, the effects of bilirubin on GSH efflux, although inhibiting the sinusoidal component in the perfused liver, might also influence the "canalicular" component in the isolated cells. Our studies cannot resolve this uncertainty, although we can be certain that a significant component of the inhibitory effect of UCB is due to its action on the sinusoidal component.
In our efforts to establish the sidedness of inhibition, we set out to delineate whether UCB had to be taken up, before it could exert an inhibitory effect on the GSH efflux. The unequivocal demonstration of the inhibitory effect of bilirubin on GSH efflux being from inside the cell was made by taking advantage of an observation reported by Wolkoff et al. (16) . Their work showed that the hepatic uptake of organic anions, including bilirubin, is dependent on the presence of extracellular Cl-and drops to zero values when Cl-' is absent in the media incubating hepatocytes or perfusing livers. Using Cl-'-free buffer, made by replacing NaCl and KCl with equimolar sucrose in the Krebs buffer, we were able to show the total absence of the effect of UCB on GSH efflux from isolated hepatocytes and perfused livers. Not only could we show that uptake was necessary for inhibition but reversibility of the inhibitory effect required complete removal ofthe cellular bilirubin.
Another complication was the fact that UCB taken up by hepatocytes was rapidly conjugated to BMG and BDG. Thus, we could not be sure which molecular form was responsible for the inhibition of GSH effilux from inside the cell. The use of UCB and homozygote Gunn rat cells, that are incapable of producing BMG and BOG, unequivocally proved that the unconjugated form of bilirubin can inhibit the GSH efflux. On the other hand, when purified BMG and BDG were used, they too were taken up and inhibited GSH efflux from isolated Sprague-Dawley, heterozygote and homozygote Gunn rat hepatocytes. Thus, it appears that UCB, BMG, and BOG are each capable of inhibiting the effiux of GSH from hepatocytes.
The similar potency of their effects, i.e., the degree of inhibition in relation to the extracellular concentrations of inhibitor used, precludes explaining the effect of BMG (and BDG) as due to deconjugation of the diglucuronide form to UCB (19) . In our experiments, the inhibitory effect of the conjugated forms of bilirubin took place in the absence of detectable cellular levels of UCB. Thus, it seems doubtful that sufficient UCB could have been generated to explain the potency of the effects we observed with the conjugated forms of bilirubin.
Our kinetic data cannot be readily modeled to distinguish the exact nature of the inhibition and/or the accurate value of the kinetic parameters ofinhibition, such as K,. This is because we are not able to identify and measure the size of the intracellular pool(s) of the inhibitor that exerts an effect on the GSH effilux. With a simplifying assumption, it is possible to fit a purely competitive kinetic model to the data representing the % inhibition of GSH efflux vs. extracellular UCB or BMG concentration. The simplifying assumption is that, in the ranges of Km of inhibitor uptake, at which we have been working (20, 21) , there might be a not-too-far from linear and oneto-one, dose-dependent relationship between the ECF and cellular concentrations of the inhibitor(s). Then, the Hill model that we have used to fit the kinetics of the uninhibited GSH efflux (3) can be expanded with a purely competitive inhibitory term, as presented before (14) , to fit our present data for UCB and BMG incubations. The outcome of such fits, using the SAAM program (22) , are shown by the curves in Figs. 4 and 5. Interestingly, the kinetic data from cells with elevated GSH can be simultaneously and consistently fitted along with that from the cells with normal GSH, using a single SAAM run (using the interrupt feature). Thus, with fairly stringent criteria for fitting the data with no more than two adjustable parameters, i.e., Kj and n (number of inhibitor sites) (14) , good fits are obtained. The Kj values extracted by our fitting exercises were 1.1±0.10 and 0.54±0. 13 ,gM (mean±SD) for ECF UCB and BMG data, respectively. However, these ought to be regarded as "apparent" or fictitious Ki values only, and the magnitude of the true K1 values could be quite different from these. In both UCB and BMG experiments, the value of n, the number of cooperative inhibitor sites per carrier unit, did not exceed 1, implying the involvement of only a single inhibitor site.
In conclusion, we have shown that organic anions, but not bile acids, when added to the perfusion or incubation media, can inhibit the sinusoidal effilux of GSH from the perfused liver and isolated hepatocytes. Bilirubin at circulating plasma levels is capable ofinhibiting the hepatic GSH effilux. All forms of bilirubin, i.e., UCB, BMG, and BDG are able to inhibit the efflux, and the inhibitory effect is exerted from inside the hepatocyte. These findings are not in conffict and, in fact, are consistent with the present knowledge and our working hypothesis of hepatic GSH efflux. Thus, organic anions enter the hepatocyte via a carrier(s), which is (are) distinct from the GSH carrier, but, once in the cell, compete with and inhibit the GSH carrier. On the other hand, the cellular GSH level has no effect on the uptake of bilirubin, but the apparent competitive inhibition by bilirubin of GSH efflux can be partially overcome by raising the cellular GSH concentration. It remains to be determined whether the efflux of organic anions is actually mediated by the GSH carrier.
Finally, our findings with respect to the effect of bilirubin on hepatic sinusoidal GSH efflux might have pathophysiological and clinical significance. Since the liver contributes > 90% of plasma GSH (2), during pathological states of hyperbilirubinemia, such as jaundice, it is possible that the efflux of he-patic GSH to the blood might be inhibited to the extent that can cause a drop in the circulating GSH. This outcome could have deleterious effects on the whole organism's capacity for defense against xenobiotics and radical oxygen products, and, thus, give rise to further complications. On the other hand, the body may compensate by elevated hepatic GSH levels to overcome the inhibition and maintain normal levels of hepatic sinusoidal GSH efflux. These questions remain to be explored.
